Literature DB >> 10446081

Heart rate variability and progression of coronary atherosclerosis.

H V Huikuri1, V Jokinen, M Syvänne, M S Nieminen, K E Airaksinen, M J Ikäheimo, J M Koistinen, H Kauma, A Y Kesäniemi, S Majahalme, K O Niemelä, M H Frick.   

Abstract

Low heart rate (HR) variability is associated with increased risk of cardiovascular morbidity and mortality, but the causes and mechanisms of this association are not well known. This prospective study was designed to test the hypothesis that reduced HR variability is related to progression of coronary atherosclerosis. Average HR and HR variability were analyzed in 12-hour ambulatory ECG recordings from 265 qualified patients participating in a multicenter study to evaluate the angiographic progression of coronary artery disease in patients with prior coronary artery bypass surgery and low high-density lipoprotein cholesterol concentrations (<1.1 mmol/L). Participants were randomized to receive a placebo or gemfibrozil therapy. The progression of coronary atherosclerosis was estimated by quantitative, computer-assisted analysis of coronary artery stenoses from the baseline angiograms and from repeated angiograms performed an average of 32 months later. The progression of focal coronary atherosclerosis of the patients randomized to placebo therapy was more marked in the tertile with the lowest standard deviation of all normal to normal R-R intervals (SDNN, 74+/-13 ms; mean decrease in the per-patient minimum luminal diameter -0.17 mm; 95% confidence interval [CI], -0.23 to -0.12 mm) than in the middle tertile (SDNN, 107+/-7 ms; mean decrease -0.05 mm; 95% CI, -0.08 to -0.01 mm) or highest tertile (SDNN, 145+/-25 ms; mean change 0.01 mm; 95% CI, -0. 04 to 0.02 mm) (P<0.001 between the tertiles). This association was abolished by gemfibrozil. SDNN was lower (P<0.001) and minimum HR was faster (P<0.01) in the patients with marked progression than in those with regression of focal coronary atherosclerosis. In multiple regression analysis including HR variability, minimum HR, demographic and clinical variables, smoking, blood pressure, glucose, lipid measurements and lipid-modifying therapy, progression of focal coronary atherosclerosis was independently predicted by the SDNN (beta=0.24; P=0.0001). Low HR variability analyzed from ambulatory ECG predicts rapid progression of coronary artery disease. HR variability provided information on progression of focal coronary atherosclerosis beyond that obtained by traditional risk markers of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446081     DOI: 10.1161/01.atv.19.8.1979

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  80 in total

Review 1.  Heart rate variability and cardiovascular mortality.

Authors:  Rollo P Villareal; Brant C Liu; Ali Massumi
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

2.  Heart rate variability: recent developments.

Authors:  Juha S Perkiömäki
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-04       Impact factor: 1.468

Review 3.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

4.  Earthing (grounding) the human body reduces blood viscosity-a major factor in cardiovascular disease.

Authors:  Gaétan Chevalier; Stephen T Sinatra; James L Oschman; Richard M Delany
Journal:  J Altern Complement Med       Date:  2012-07-03       Impact factor: 2.579

5.  Relationship between resting electrocardiographic parameters and estimated 10-year risk for coronary heart disease in healthy adults in the USA.

Authors:  Jong-Min Lee; Ki-Dong Yoo; Yong-Seog Oh; Dong-Bin Kim; Chan-Seok Park; Sung-Won Jang; Ji-Hoon Kim; Sang-Hyun Ihm; Hee-Yeol Kim; Man-Young Lee; Ki-Bae Seung; Tai-Ho Rho
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-10       Impact factor: 1.468

6.  Resting heart rate and the risk of death and cardiovascular complications in patients with type 2 diabetes mellitus.

Authors:  G S Hillis; M Woodward; A Rodgers; C K Chow; Q Li; S Zoungas; A Patel; R Webster; G D Batty; T Ninomiya; G Mancia; N R Poulter; J Chalmers
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

Review 7.  Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms.

Authors:  Paolo Palatini
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Heart rate variability and intima media thickness.

Authors:  Nanna Hurwitz Eller; Birgitta Malmberg; Peter Bruhn
Journal:  Int J Behav Med       Date:  2006

9.  Vagally-mediated heart rate variability and indices of well-being: Results of a nationally representative study.

Authors:  Richard P Sloan; Emilie Schwarz; Paula S McKinley; Maxine Weinstein; Gayle Love; Carol Ryff; Daniel Mroczek; Tse-Hwei Choo; Seonjoo Lee; Teresa Seeman
Journal:  Health Psychol       Date:  2016-08-29       Impact factor: 4.267

10.  Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.

Authors:  Fabio Mangiacapra; Iginio Colaiori; Elisabetta Ricottini; Francesco Balducci; Antonio Creta; Chiara Demartini; Giorgio Minotti; Germano Di Sciascio
Journal:  Clin Res Cardiol       Date:  2016-08-12       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.